2021
DOI: 10.3390/cancers13071663
|View full text |Cite
|
Sign up to set email alerts
|

Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer

Abstract: Platinum-resistant ovarian cancer (OC) has limited treatment options and is associated with a poor prognosis. There appears to be an overlap between molecular mechanisms responsible for platinum resistance and immunogenicity in OC. Immunotherapy with single agent checkpoint inhibitors has been evaluated in a few clinical trials with disappointing results. This has prompted exploration of immunotherapy combination strategies with chemotherapy, anti-angiogenics, poly (ADP-ribose) polymerase (PARP) inhibitors and… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
19
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 21 publications
(19 citation statements)
references
References 112 publications
(102 reference statements)
0
19
0
Order By: Relevance
“…Ovarian cancer is the fifth leading cause of death for women. In 2018, new cases of ovarian cancer diagnosis patients reached around 21,750 in the United States (US); an additional 13,940 deaths were also reported [40].…”
Section: Libs Analysis For Different Cancers Ovarian Cancermentioning
confidence: 99%
“…Ovarian cancer is the fifth leading cause of death for women. In 2018, new cases of ovarian cancer diagnosis patients reached around 21,750 in the United States (US); an additional 13,940 deaths were also reported [40].…”
Section: Libs Analysis For Different Cancers Ovarian Cancermentioning
confidence: 99%
“…Women with platinum-resistant recurrent OC (ROC) continue to have a poor prognosis with limited treatment options. 2 3 Therefore, there is a clear unmet need to improve outcomes in this subset of patients.…”
Section: Introductionmentioning
confidence: 99%
“…Immunotherapy can improve autoimmunity, and then effectively prevent and control the occurrence of OC (Rocconi et al, 2020). However, not all patients show the same degree of sensitivity to immunotherapy (Indini et al, 2021). Therefore, the study of the relationship between the immune microenvironment (TME) and the prognosis of OC at the molecular level is of great signi cance for screening the population with the best bene t from the immunotherapy.…”
Section: Discussionmentioning
confidence: 99%